Skip to main content
. 2016 May 16;126(6):2077–2092. doi: 10.1172/JCI87037

Figure 2. Inhibition of SHP2 activity reduces skin lesions, decreases splenomegaly, normalizes kidney structure and function, and prolongs MRL/lpr longevity.

Figure 2

Representative photographs of (A) skin lesions or (B) spleens from WT, MpJ, and MRL/lpr mice treated with vehicle or 11a-1 for 6 weeks. (C) Spleen weight to tibia length ratios (n = 8 mice/group) and (D) total splenocyte counts (n = 3–5 mice/group) from 18-week-old WT, MpJ, and MRL/lpr female mice treated for 6 weeks with either vehicle or 11a-1 (7.5 mg/kg/d). (E) Representative photograph of kidneys, (F) histograms showing kidney weight to tibia length (n = 8 mice/group), and (G) ratio of albumin to creatinine in urine (n = 7–8 mice per group), and (H) representative H&E-stained kidney sections and pathological scores (n = 4 mice/group) from 18-week-old WT, MpJ, and MRL/lpr female mice treated for 6 weeks with vehicle or 11a-1 (7.5 mg/kg/d). Scale bar: 500 μm. (I) Body weight measurements for 12- to 18-week-old WT, MpJ, and MRL/lpr mice subjected to either vehicle or 11a-1 (n = 8 mice/group). (J) Kaplan-Meier survival curve in 12- to 26-week-old WT, MpJ, and MRL/lpr mice subjected to either vehicle or 11a-1. n = 5 mice/group. Note: all vehicle-treated MRL/lpr mice died by 26 weeks, whereas only 20% of the 11a-1–treated mice died at that same time point. *P < 0.01; #P < 0.05, where P values were derived from 2-way ANOVA with Holm-Sidak post-test when ANOVA was significant.